Navigation Links
CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate

SEOUL, South Korea, May 10 /PRNewswire/ -- CrystalGenomics, Inc., a novel drug R&D company announced today that the Phase I SAD (Single Ascending Dose) study for its novel antibiotic candidate, CG400549, has been successfully completed in Europe.

CG400549 is a potential first-in-class antibiotic candidate targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme in generating bacterial membrane) as it has novel chemical structure which has never been used as an antibacterial agent previously. CG400549 is being developed to target the notorious resistant bacterial strains including MRSA (Methicillin Resistant Staphylococcus aureus) and VRSA (Vancomycin Resistant Staphylococcus aureus), or commonly referred to as the "super bug." CG400549 has successfully completed the Phase I SAD study in Europe and has just received an approval for its Phase I MAD (Multiple Ascending Dose) study from the Ethics Committee.

The objective of the SAD study was to evaluate safety, tolerability and pharmacokinetic characteristics of CG400549 in healthy volunteers. The study demonstrated that CG400549 was safe and well tolerated among all subjects.  

Now that the Ethics Committee has granted an approval for the MAD study, CrystalGenomics plans to initiate the study which will further examine the safety and tolerability profiles of CG400549.

Joong Myung Cho, Ph.D., President & CEO of CrystalGenomics said: "We are very pleased with the SAD study results and this enables us to begin the next Phase I study with a high level of confidence. We anticipate completing the MAD study and will make our transition into Phase IIa clinical trial by the end of this year."

About CrystalGenomics

CrystalGenomics, Inc. is a publicly-held company dedicated to the discovery and development of novel drug candidates in the areas of cancer, CNS, inflammation, and infectious diseases. The lead candidate, CG100649 is a next generation NSAID which has completed a Phase IIa trial in Europe and CG200745 for molecular target cancer therapeutics is Phase I ready. The company has competitive and proprietary platform technologies for structural biology, structure-based novel scaffold/lead design, lead optimization and candidate selection. CrystalGenomics is headquartered in Seoul, Korea and its subsidiary, CG Pharmaceuticals Inc., is located in Emeryville, California for US and EU clinical management. For more information on CrystalGenomics, please visit:

CONTACT: Steven Kim, +82-2-3010-8611,

SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals Announces Public Offering of Common Stock
2. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
3. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
4. CareFusion Announces Agreement With Banner Health to Upgrade and Extend Pyxis Medication Solutions
5. Xanodyne Announces Renewed Focus on Pain Management Market
6. Medco Announces Webcast for Annual Meeting of Shareholders
7. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer
8. Hill-Rom Announces Third Quarter 2010 Dividend
9. Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2010 Results
10. ADVENTRX Pharmaceuticals Announces Closing of Financing
11. China Pharma Holdings, Inc. Announces May Investor Conference Participation
Post Your Comments:
(Date:11/24/2015)... 24, 2015 iRhythm Technologies, Inc. , a leading ... announced that it will participate in the 27th Annual Piper Jaffray ... New York, NY . Kevin King , Chief ... 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm is ...
(Date:11/24/2015)... Teledyne DALSA , a Teledyne Technologies company ... introduce its CMOS X-Ray detector for mammography at ... December 3, at McCormick Place in Chicago ... interventional imaging will be on display in the South Hall, ... CMOS X-Ray detectors is the industry benchmark for high speed ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... , ... Aided by seed funding from the Ron Foley Foundation, researchers at ... into how to detect and treat pancreatic cancer (PC). , WCHN researchers will ... molecules (ncRNA), genetic material that is present in the blood of patients with PC. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... for its exceptional customer service: the TrustDale certification. The award recognizes good companies ... Baltimore stone honing , tile and grout, and hard surface restoration company earned ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... patented products, announces Innovative Blending, a household invention that revolutionizes the vending machine ... & Smoothie Bars market is worth $2 billion," says Scott Cooper, CEO and ...
(Date:11/24/2015)... ... November 24, 2015 , ... GBCHealth and Global Health ... bestowed annually to the world’s best corporate-supported global health programs. The awards ... Landscape Symposium held in Washington D.C and attended by over 150 representatives from ...
(Date:11/24/2015)... Miami, Fl (PRWEB) , ... November 24, 2015 , ... ... Farms. Adding houseplants is an easy and affordable way to bring long-lasting style and ... “green heroes” also provide oxygen, clean the air and keep on giving all year ...
Breaking Medicine News(10 mins):